MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grew
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue declined year-over-year due to BARDA timing, but full-year guidance of $24–26 million was reaffirmed. EscharEx and NexoBrid programs advanced, with NexoBrid achieving record U.S. sales and a new Vericel agreement expected to boost H2 revenue.Original document: MediWound Ltd. [MDWD] SEC 6-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue declined year-over-year due to BARDA timing, but full-year guidance of $24–26 million was reaffirmed. EscharEx and NexoBrid programs advanced, with NexoBrid achieving record U.S. sales and a new Vericel agreement expected to boost H2 revenue.
Original document: MediWound Ltd. [MDWD] SEC 6-K Current Report — Aug. 13 2026